The management of non-muscle-invasive bladder cancer: A comparison of European and UK guidelines

Abstract

Bladder cancer represents a significant health burden worldwide, with non-muscle-invasive tumours representing the majority of new bladder cancer diagnoses. Non-muscle-invasive bladder cancer (NMIBC) has a high prevalence and forms a large proportion of the caseload in urological practice, accounting for a significant cost in terms of urological healthcare. The last two decades have seen the development and refinement of guidelines from national and international organisations aiming to optimise management of NMIBC and bladder cancer in general. This review outlines the most recent European and United Kingdom guidelines on NMIBC, and in particular focuses on comparing and contrasting key recommendations from guidelines published by the European Association of Urology and the UK-based National Institute for Clinical Excellence.

Level of evidence: Not applicable for this multicentre audit.

Keywords

Bladder cancer superficial NMIBC guidelines

Get full access to this article

View all access options for this article.

References

Jemal

Bray

Center

et al . Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.

Burger

Catto

Dalbagni

et al . Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234–241.

Cancer Research UK. Bladder cancer statistics. 2013. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer (accessed 16 June 2016)

Bosetti

Bertuccio

Chatenoud

et al . Trends in mortality from urologic cancers in Europe, 1970–2008. Eur Urol 2011; 60: 1–15.

Chavan

Bray

Lortet-Tieulent

et al . International variations in bladder cancer incidence and mortality. Eur Urol 2014; 66: 59–73.

Babjuk

Böhle

Burger

et al . EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol 2017; 71: 447–461.

National Institute for Health and Care Excellence. Bladder cancer: Diagnosis and management. 2015. https://www.nice.org.uk/guidance/ng2/resources/bladder-cancer-diagnosis-and-management-pdf-51036766405 (accessed 3 June 2016).

van der Meijden

Oosterlinck

Brausi

et al . Significance of bladder biopsies in Ta,T1 bladder tumors: A report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol 1999; 35: 267–271.

Hara

Takahashi

Gondo

et al . Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: Retrospective analysis of 173 Japanese cases. Int J Urol 2009; 16: 293–298.

10.

Abern

Owusu

Anderson

et al . Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: A systematic review and meta-analysis. J Natl Compr Canc Netw 2013; 11: 477–484.

11.

Sylvester

Oosterlinck

van der Meijden

AP.

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol 2004; 171 (6 Pt 1): 2186–2190, quiz 2435.

12.

Perlis

Zlotta

Beyene

et al . Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: An updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol 2013; 64: 421–430.

13.

Brausi

Collette

Kurth

et al . Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies. Eur Urol 2002; 41: 523–531.

14.

Grimm

Steinhoff

Simon

et al . Effect of routine repeat transurethral resection for superficial bladder cancer: A long-term observational study. J Urol 2003; 170: 433–437.

15.

Divrik

Yildirim

Zorlu

et al . The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: A prospective, randomized clinical trial. J Urol 2006; 175: 1641–1644.

16.

Divrik

Yildirim

Eroğlu

et al . Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 2006; 175: 1258–1261.

17.

Sylvester

van der Meijden

Oosterlinck

et al . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466–465; discussion 475–477.

18.

Fernandez-Gomez

Madero

Solsona

et al . Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: The CUETO scoring model. J Urol 2009; 182: 2195–2203.

19.

Holmang

Andius

Hedelin

et al . Stage progression in Ta papillary urothelial tumors: Relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001; 165: 1124–1128; discussion 1128–1130.

20.

Borhan

Reeder

O’Connell

et al . Grade progression and regression in recurrent urothelial cancer. J Urol 2003; 169: 2106–2109.

21.

Gofrit

Pode

Lazar

et al . Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 2006; 49: 303–306; discussion 306–307.

22.

Soloway

Bruck

Kim

. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003; 170: 438–441.

23.

Mariappan

Smith

. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 2005; 173: 1108–1111.